Living Cell Technologies Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LVCLY research report →
About the company
Living Cell Technologies Limited (LCT) is a biotechnology company dedicated to the innovation, development, and market introduction of regenerative medical therapies. These treatments leverage naturally occurring cells with the aim of restoring physiological functions, particularly within New Zealand. A primary focus for LCT is NTCELL, a novel alginate-coated capsule currently progressing through Phase IIb clinical trials for its application in treating Parkinson's disease.
- CEO
- David Richard Hainsworth
- IPO
- 2008
- Employees
- 48
- HQ
- Sydney, NSW, AU
Price Chart
- Market Cap
- $11.39M
- P/E
- -11.54
- P/S
- 195.96
- P/B
- 8.03
- EV/EBITDA
- -13.57
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1659.45%
- Net Margin
- -1673.77%
- ROE
- -61.85%
- ROIC
- -68.93%
- Revenue
- $0 · -100.00%
- Net Income
- $-2,095,562 · 0.57%
- EPS
- $-0.01 · 18.75%
- Op Income
- $-2,200,720
- FCF YoY
- 23.31%
- 52W High
- $0.08
- 52W Low
- $0.02
- 50D MA
- $0.04
- 200D MA
- $0.05
- Beta
- 0.76
- Avg Volume
- 919
Get TickerSpark's AI analysis on LVCLY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LVCLY coverage
Recent articles, reports, and earnings notes.
No research on LVCLY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LVCLY report →Similar companies
Peers in the same neighborhood.